Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Angioplasty or medical therapy in patients with documented ischemia

Original title: Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: A collaborative meta-analysis of contemporary randomized clinical trials. Reference: Stergiopoulos K el al. JAMA Intern Med 2013; DOI:10.1001/jamainternmed.2013

The amount in ischemic patients with stable coronary heart disease is associated with poor prognosis. However, it is unclear whether revascularization to reduce that amount also reduces ischemic events compared with medical treatment.

This meta- analysis included major works that randomized patients with stable coronary artery disease and demonstrated ischemia  to revascularization or medical treatment (MASS II , COURAGE , BARI 2D , FAME 2, etc.) . A total of 4064 patients, all with documented ischemia by stress test, gamma camera, echo stress or fractional flow reserve were analyzed. The endpoints included in the analysis were death from any cause, nonfatal myocardial infarction, urgent revascularization and angina. With a median follow-up of 5 years,  mortality rate from all causes was observed in the group receiving revascularization by angioplasty  versus  those who only received medical treatment  6.5 % and 7.3 % respectively (OR 0.90 CI 95% 0.71 to 1.16; p= ns) , nonfatal myocardial infarction 9.2 % and 7.6% (OR 1.24 CI 95% 0.99 to 1.56; p=ns) , urgent revascularization 18.3 % and  28.4 % (OR 0.64, CI 95% 0.35 to 1.17) and angina 20.3 % and 23.3 % (OR 0.91, CI 95% 0.57 to 1.44).

Conclusion:

In patients with stable coronary artery disease and documented ischemia, percutaneous revascularization does not seem to reduce events compared with medical treatment alone.

Editorial comment

This work, like all meta-analyzes, drag the limitations of the studies in which it was based. For example, ischemia was documented in all patients but as a binary variable. If we know that the greater ischemia increased mortality, why not also expect a different benefit with revascularization according to the amount. The same should be considered for symptoms; to worse major functional class a greater relief should be by revascularization. Finally the localization of the ischemic territory is taken into account in daily practice but has been difficult to differentiate in the works and should be taken into consideration. Perhaps some of these questions can be answered by the 8000 patients that ISCHEMIA study plans to include. 

SOLACI.ORG

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...

DOUBLE-CHOICE: Lower Pacemaker Implantation Rates with ACURATE neo2 Compared with Evolut in Patients Undergoing TAVI

The DOUBLE-CHOICE trial is a multicenter, randomized, controlled study conducted in Germany to evaluate the performance of next-generation transcatheter heart valves and different anesthesia...